Acquired thrombotic thrombocytopenic purpura is a rare blood disorder with a high early mortality rate, if untreated. Standard of care plasma exchange and glucocorticoids have dramatically improved survival. However, additional advancements are necessary to further decrease mortality. Caplacizumab-yhdp (Cablivi®) is the first Food and Drug Administration-approved treatment indicated for adult patients with acquired thrombotic thrombocytopenic purpura, in combination with plasma exchange and immunosuppressive therapy. However, there are considerable risks associated with the use of caplacizumab and they must be weighed against the benefits of the medication.
LevyGGNicholsWCLianEC, et al.
Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.Nature2001;
413: 488–494.
3.
BandarenkoNBrecherME.United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. J Clin Apher1998;
13: 133–141.
4.
WestwoodJPThomasMAlwanF, et al.
Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens. Blood Adv2017;
1: 1159–1166.
5.
ScullyMMcDonaldVCavenaghJ, et al.
A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura.Blood2011;
118: 1746–1753.
6.
PageEEHovingaJAKTerrellDR, et al.
Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura.Blood2016;
127: 3092–3094.
7.
ScullyMHuntBJBenjaminS, et al.
Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies.Br J Haematol2012;
158: 323–335.
Caplacizumab. Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: http://online.lexi.com. Accessed April 29, 2019.
10.
CABLIVI (caplacizumab-yhdp) Highlights of Prescribing Information. Ghent (Zwijnaarde), Belgium: Ablynx; Feb 2019.
11.
BannasPHambackJKoch-NolteF.Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics. Front Immunol2018;
8(1603): 1–13.
12.
ScullyMCatalandSRPeyvandiF, et al.
Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med2019;
380: 335–336.
13.
PeyvandiFScullyMKremer HovingaJA, et al.
Caplacizumab for acquired thrombotic thrombocytopenic purpura.N Engl J Med2016;
374: 511–522.
14.
PeyvandiFScullyMKremer HovingaJA, et al.
Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.J Thromb Haemost2017;
15: 1448–1452.
15.
ClinicalTrials.gov [Internet]2018. National Library of Medicine (US). 2018 Dec. Identifier NCT02878603, Follow-up study for patients who completed study ALX0681-C301 (Post-HERCULES). Available at: https://clinicaltrials.gov/ct2/show/NCT02878603. Accessed May 11, 2019.
16.
CatalandSRScullyMPeyvandiF, et al.
Risk factors and manageability of the mainly mild mucocutaneous bleeding profile observed in aTTP patients treated with caplacizumab during the phase III HERCULES study. Blood2018;
132: 1142.
17.
BalduiniCLGugliottaLLuppiM, et al.
High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study.Ann Hematol2010;
89: 591–596.
18.
HeidelFLipkaDBvon AuerC, et al.
Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia.Thrombosis Haemostasis2007;
97: 228–233.
19.
LimWVeselySKGeorgeJN.The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura.Blood2015;
125: 1526–1531.
20.
ChenHFuAWangJ, et al.
Rituximab as first-line treatment for acquired thrombotic thrombocytopenic purpura.J Int Med Res2017;
45: 1253–1260.
21.
SayaniFAAbramsCS.How I treat refractory thrombotic thrombocytopenic purpura.Blood2015;
125: 3860–3867.
22.
PrasadVKimCBurottoM, et al.
The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses. JAMA Intern Med2015;
175: 1389–1398.
23.
WuNLiuJYangS, et al.
Diagnostic and prognostic values of ADAMTS13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thrombocytopenic purpura. Transfusion2015;
55: 18–24.
24.
WeinbauerGFVogelF.Challenges in nonhuman primate research in the 21st century.
Münstery:
Waxmann, 2012.
25.
CatalandSRKourlasPJYangS, et al.
Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura.Blood Adv2017;
1: 2075–2082.
26.
CukerA.Caplacizumab for TTP: a temporizing measure for a relapsing disease. Hematologist ASH News Rep2016;
13: 9.
27.
UhlLKissJEMalynnE, et al.
Rituximab for thrombotic thrombocytopenic purpura: lessons from the STAR trial.Transfusion2017;
57:2532–2538.
28.
WintersJLBrownDHazardE, et al.
Cost-minimization analysis of the direct costs of TPE and IVIG in the treatment of Guillain-Barre syndrome. BMC Health Serv Res2011;
11: 101–108.
29.
Rituximab. Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: http://online.lexi.com. Accessed May 24, 2019.
30.
Antihemophilic Factor/von Willebrand Factor Complex (Human). Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: http://online.lexi.com. Accessed May 24, 2019.
